Brought to you by 
BTG, Collegium Pharmaceutical develop sleep apnea therapy
01 Nov 2004
Executive Summary
BTG PLC (in-licenser, develops and sells products and technologies) and specialty drug company Collegium Pharmaceutical have teamed up to create a new formulation of a BTG combination therapy that is about to enter preclinical studies for sleep apnea.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BTG, Collegium Pharmaceutical develop sleep apnea therapy
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice